Atazanavir (Reyataz)

The Latest

Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir

Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.

By Mark Mascolini

What's Hot in HIV Clinical Science

What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.

By Sony Salzman

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study

Atazanvir/ritonavir at 200/100 mg was found to be non-inferior to atazanvir/ritonavir at 300/100 mg, according to study results presented at IAS 2015.

By Polly Clayden for HIV i-Base

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.

By Myles Helfand

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...

By Simon Collins for HIV i-Base

Transplacental Transfer of Atazanavir and Neonatal Hyperbilirubinemia

Results from a study evaluating the transplacental transfer of atazanavir (ATV) and the incidence of hyperbilirubinaemia in ATV exposed neonates were presented at the 14th International Workshop on Clinical Pharmacology.

In this analysis, foetal cor...

By Polly Clayden for HIV i-Base

Recent Changes to the Reyataz (Atazanavir Sulfate) Capsule Labeling

Recently FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes.

Section 5 Warnings and Precautions was revised to include cholelithiasis as follows:

Nephrolithiasis and Cholelithiasis

Cases of n...

By U.S. Food and Drug Administration

Reyataz and Kidney Stones

Reyataz, one of two preferred HIV protease inhibitor (PI) medications under U.S. treatment guidelines, is associated with the risk of kidney stones and other potential renal abnormalities. According to Japanese researchers, people taking Norvir-boost...

By Jeff Berry and Enid Vazquez for Positively Aware

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors

The FDA has approved an 800-mg tablet of darunavir for treatment naive patients. This single tablet will obviously replace the two darunavir 400-mg tablets in first-line therapy. (Yes, my math is that good.) Darunavir will still require 100-mg ritona...

By Paul E. Sax, M.D. for NEJM Journal Watch

HIV JournalView: September 2012

We tell our patients that HIV has become like other chronic diseases -- and, largely, we believe it. These patients are aging along with us, and clinic visits have become more like routine checkups with continued praise for undetectable viral loads a...

By David Alain Wohl, M.D.